# Table 3 Incidence, clearance and prevalence of overall HR-HPV infections at one-year follow-up by age

Age group

Crude prevalence, n/N (%)

Adjusted prevalence, n/N (%)

Adjusted incidence, n/N (%)

Clearance, n/N (%)

Pa

25-29

15/102 (14.7)

28/302 (9.3)

21/269 (7.8)

26/33 (78.8)

0.560

30-34

35/242 (14.5)

51/598 (8.5)

24/541 (4.4)

30/57 (52.6)

0.497

35-39

91/494 (18.4)

141/1 275 (11.1)

82/1 145 (7.2)

71/130 (54.6)

0.419

40-44

100/593 (16.9)

163/1 503 (10.8)

105/1 339 (7.8)

106/164 (64.6)

1.000

45-49

97/552 (17.6)

125/1 390 (9.0)

57/1 235 (4.6)

87/155 (56.1)

0.015

50-54

91/345 (26.4)

108/877 (12.3)

43/765 (5.6)

47/112 (42.0)

0.752

55-59

100/315 (31.7)

116/801 (14.5)

33/667 (4.9)

51/134 (38.1)

0.063

60-65

46/148 (31.1)

56/363 (15.4)

22/316 (7.0)

13/47 (27.7)

0.175

Total

575/2 791 (20.6)

788/7 109 (11.1)

387/6 277 (6.2)

431/832 (51.8)

0.133

1. NOTE: Since only a portion of baseline screen negative women were followed up at one-year, incidence was adjusted for the sampling fraction. It was calculated as follows: ((1/sampling fraction) * (Number of baseline screen negatives who tested careHPV-positive at follow-up)â€‰+â€‰(Number of baseline screen positives with careHPV-negative who tested careHPV-positive at follow-up)) / ((Number of baseline screen negatives)â€‰+â€‰(Number of baseline screen positives with careHPV-negative who were followed up)). The clearance was simply calculated by: (Number of cleared) / (Number of baseline careHPV-positive who were followed up). The adjusted prevalence at follow up was determined as: ((Number of baseline careHPV-positives who were not cleared)â€‰+â€‰(Number of incidence)) / Total population. Age groups were defined on the basis of age at baseline. a: the McNemar x2 test is used to test for statistical differences in clearance and incidence; bold type indicates statistical significance (pâ€‰<â€‰0.05).